GSK Hits Apotex With Suit Over Bid For Generic Prostate Drug

Law360, New York (August 31, 2012, 6:55 PM EDT) -- GlaxoSmithKline PLC hit generic drugmaker Apotex Inc. with a lawsuit Thursday, claiming the company's planned generic version of prostate drug Avodart would infringe one of GSK's patents.

London-based GSK said Apotex filed an abbreviated new drug application with the U.S. Food and Drug Administration for approval to sell 0.5 milligram capsules of dutasteride, the active ingredient in Avodart, a drug used to treat symptoms of a swollen prostate gland.

Avodart is protected by U.S. Patent Number 5,565,467, entitled androstenone derivative, which was issued by the U.S....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.